Allred D C, Bustamante M A, Daniel C O, Gaskill H V, Cruz A B
Department of Pathology, University of Texas Health Science Center, San Antonio 78284.
Arch Surg. 1990 Jan;125(1):107-13. doi: 10.1001/archsurg.1990.01410130113018.
An estrogen receptor-immunocytochemical assay (ER-ICA) was performed on frozen sections of 130 samples of human breast carcinoma. A standard dextran-coated charcoal assay (DCCA) was performed on the same samples. Concordance of results between the tests was 91%. The sensitivity and specificity of the ER-ICA, compared with the DCCA, were 92% and 89%, respectively. We describe the ER-ICA technique and review the literature regarding the use of the ER-ICA in evaluating breast cancer with respect to the agreement of results with the DCCA, the nature of discordant results, the ability to predict the clinical response to hormone therapy, and the ability to predict disease-free survival. The combined experience of many studies has shown that the ER-ICA is a highly specific and sensitive method for measuring the level of ERs in breast tumors with a high level of agreement with the DCCA. Early experience has suggested that the ER-ICA can predict the response to hormone therapy and disease-free survival, as well as or better than the DCCA. The evaluation of receptor heterogeneity, made possible by the ER-ICA, may enhance our ability to discriminate ER-positive tumors with a relatively high risk of recurrence.
对130份人乳腺癌样本的冰冻切片进行了雌激素受体免疫细胞化学检测（ER-ICA）。对相同样本进行了标准的葡聚糖包被活性炭检测（DCCA）。两项检测结果的一致性为91%。与DCCA相比，ER-ICA的敏感性和特异性分别为92%和89%。我们描述了ER-ICA技术，并就ER-ICA在评估乳腺癌方面的应用进行文献综述，内容涉及与DCCA结果的一致性、不一致结果的性质、预测激素治疗临床反应的能力以及预测无病生存期的能力。多项研究的综合经验表明，ER-ICA是一种高度特异且敏感的方法，用于测量乳腺肿瘤中雌激素受体水平，与DCCA具有高度一致性。早期经验表明，ER-ICA能够预测激素治疗反应和无病生存期，效果与DCCA相当或更佳。ER-ICA使得对受体异质性的评估成为可能，这可能会增强我们鉴别具有相对较高复发风险的ER阳性肿瘤的能力。
